These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25149424)

  • 1. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.
    Shlyankevich J; Mehta NN; Krueger JG; Strober B; Gudjonsson JE; Qureshi AA; Tebbey PW; Kimball AB
    Am J Med; 2014 Dec; 127(12):1148-53. PubMed ID: 25149424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
    Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
    Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis and cardiovascular comorbidities with emphasis in Asia.
    Chu TW; Tsai TF
    G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.
    Furue M; Tsuji G; Chiba T; Kadono T
    Intern Med; 2017; 56(13):1613-1619. PubMed ID: 28674347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
    Menter MA; Mehta NN; Lebwohl MG; Gottlieb AB; Mendelsohn AM; Rozzo SJ; Leonardi C
    J Drugs Dermatol; 2020 Aug; 19(8):703-708. PubMed ID: 32845115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives.
    Kapniari E; Papadimitriou P; Dalamaga M; Makavos G; Piaserico S; Egeberg A; Ikonomidis I; Papadavid E
    Curr Vasc Pharmacol; 2020; 18(6):592-609. PubMed ID: 32445456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.
    Pannu S; Rosmarin D
    Am J Clin Dermatol; 2021 May; 22(3):293-300. PubMed ID: 33586126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis and cardiovascular disorders.
    Frieder J; Ryan C
    G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
    Ryan C; Kirby B
    Dermatol Clin; 2015 Jan; 33(1):41-55. PubMed ID: 25412782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.
    Wu JJ; Kavanaugh A; Lebwohl MG; Gniadecki R; Merola JF
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):797-806. PubMed ID: 35238067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiometabolic risk in psoriasis: differential effects of biologic agents.
    Kaplan MJ
    Vasc Health Risk Manag; 2008; 4(6):1229-35. PubMed ID: 19337536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double trouble: psoriasis and cardiometabolic disorders.
    Mahyoodeen NG; Crowther NJ; Tikly M
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):189-194. PubMed ID: 29293257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
    Torres T; Raposo I; Selores M
    Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis as the marker of underlying systemic disease.
    Kourosh AS; Miner A; Menter A
    Skin Therapy Lett; 2008 Feb; 13(1):1-5. PubMed ID: 18357363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic mechanisms shared between psoriasis and cardiovascular disease.
    Ghazizadeh R; Shimizu H; Tosa M; Ghazizadeh M
    Int J Med Sci; 2010 Aug; 7(5):284-9. PubMed ID: 20827428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis as a systemic disease.
    Grozdev I; Korman N; Tsankov N
    Clin Dermatol; 2014; 32(3):343-50. PubMed ID: 24767182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
    Armstrong AW; Gelfand JM; Boehncke WH; Armstrong EJ
    J Rheumatol; 2013 Aug; 40(8):1434-7. PubMed ID: 23908540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome in patients with psoriatic disease.
    Gelfand JM; Yeung H
    J Rheumatol Suppl; 2012 Jul; 89():24-8. PubMed ID: 22751586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis and cardiovascular disorders.
    Ryan C; Menter A
    G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.